[Clinical treatment of peripheral arterial occlusive diseases].
Effectiveness and tolerance of Defluina was studied in a selective open trial including 30 patients (17 males, 13 females, mean age 70 years) suffering from peripheral arterial occlusive diseases of different stages. All patients were treated with Defluina, 20 drops thrice a day during a mean period of 30 days. Simultaneous application of further peripheral vasodilators was excluded. Subjective and objective parameters (pulse, Ratschow's test, walking distance) of 27 patients (15 males, 12 females) were evaluated. After 4 weeks of therapy an improvement of all parameters especially of the walking distance was observed. Within 4 weeks 3 of 5 ulcera cruris as well as an initially existing gangrene were closed. Deflunia was well tolerated by 25 patients, very well tolerated by 2. The therapy was discontinued in 3 patients: 2 because of unchanged complaints after 13 and 20 days of therapy, 1 after 17 days due to dull gastric pain following intake of the drug. Cardiac side-effects or steal phenomena were not observed.
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004087:Dihydroergotamine / Q000008:administration & dosage* / Q000009:adverse effects; D004088:Dihydroergotoxine / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004341:Drug Evaluation; D004877:Ergoloid Mesylates / Q000008:administration & dosage*; D004879:Ergotamines; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D015016:Yohimbine / Q000008:administration & dosage* / Q000009:adverse effects
D004338:Drug Combinations; D004879:Ergotamines; D004088:Dihydroergotoxine; D015016:Yohimbine; D004087:Dihydroergotamine; D004877:Ergoloid Mesylates
Zur klinischen Behandlung peripherer arterieller Durchblutungsstörungen